Healtheuniverse Announces Shareholder Letter From CEO Dr. Vipul Dev, MD Healtheuniverse Inc. (OTC: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that the following shareholder letter was released today by Chief Executive Officer Dr. Vipul Dev, MD.
Dear Fellow Shareholders:
"Healtheuniverse has made a series of announcements this quarter that further demonstrate our commitment to tackling the most difficult challenges of adult stem cell therapy development. With our vision for commercialized therapies utilizing non-embryonic stem cells, we've introduced a strategy for addressing critical areas of delivering stem cell therapies that can be utilized internationally and profitably. These solutions will target four key areas -- Core Research, Patented and Proprietary Technologies, Commercialization Focus, and Product Delivery. Each solution is architected to align people, process and technology with the goal of delivering greater control and predictability in this pioneering field of medicine.
"In support of this strategy we have announced we are acquiring the California Institute of Plastic and Reconstructive Surgery, a company focused on the latest techniques in Cosmetic Surgery and extensive new developments in the field of Reconstructive Surgery. We expect this acquisition to close shortly. CICRS has and continues to deliver a strong reputation in the market for delivering best-in-class Cosmetic Surgery applications such as breast augmentation, facelifts, liposuction, and rhinoplasty, as well as extensive Reconstructive Surgery for Breast Cancer, burn victims, trauma victims, chronic wounds, skin cancer, and hand surgery. CICRS also shares Healtheuniverse's vision for an approach to delivering the first adult stem cell based therapies that spans the entire market for plastic and reconstructive surgery. This acquisition adds a vital component to our overall strategy and will form the cornerstone of our stem cell based commercialization model.
"Our plan is to create additional value, cash flow and market breadth through additional acquisitions in the plastic surgery arena as well as companies that complement our research, creating a true organic growth and acquisition based business model. You will see Healtheuniverse's approach is aggressive yet financially responsible with investments that align people, processes and technologies across our corporate organization.
"Through these moves, I hope one message is clear...Healtheuniverse is methodically executing on our vision to become a leader in the field of adult stem cell research and commercialization. Our commitment to this vision is guiding major decisions and strong investments that enable Healtheuniverse to deliver new levels of value for our shareholders. Today Healtheuniverse has an unmatched combination of depth of research solutions and breadth of commercialization strategies to tackle the non-embryonic stem cell industry's most challenging business issues. We're excited about this direction and the future we share together."
About HEALTHeUNIVERSE Inc.
HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Healtheuniverse Completes Acquisition of the California Institute of Cosmetic and Reconstructive Surgery; Revenue and Earnings Reflected in 2nd Quarter 2006 Financials Acquisition Includes CICRS Clinical Database Advancing Capacity for Adult Stem Cell Clinical Trials Healtheuniverse Inc. (OTC: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that it has completed the acquisition of the assets, operations and clinical database of The California Institute of Cosmetic & Reconstructive Surgery. Revenue and Earnings from the acquisition will be reflected in the 2nd quarter financials and is expected to be accretive to earnings.
The acquisition includes the CICRS clinical database, which expands and advances the Company's capacity for evidence-based human clinical trials for stem cell applications in the plastic, reconstructive, and cosmetic surgery market. This acquisition marks a significant benchmark in the Companies progress to be the first to commercialize the use of regenerative medicine and adult stem cells.
Services at the California Institute of Cosmetic & Reconstructive Surgery range from the latest techniques in Cosmetic Surgery to extensive new developments in the field of Reconstructive Surgery. The Institute performs Cosmetic Surgery such as breast augmentation, facelifts, liposuction, and rhinoplasty, as well as extensive Reconstructive Surgery for Breast Cancer, burn victims, trauma victims, chronic wounds, skin cancer, and hand surgery.
Dr Vipul Dev MD, Chief Executive Officer of Healtheuniverse, Inc., stated, "The successful completion of the acquisition of CICRS is a significant milestone in the growth of Healtheuniverse. With substantial growth in the area of plastic and reconstructive surgery and our adult stem cell research moving towards clinical trials we believe the acquisition is a cornerstone to our development. We are now moving forward with our plans to accelerate development of our non-embryonic stem cell therapies, which should result in advancement of the technology and value for our shareholders."
About HEALTHeUNIVERSE Inc.
HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Healtheuniverse Announces Corporate Update; Pursuing New Lab Facilities and Major Pre-Clinical Stem Cell Trials Healtheuniverse Inc. (PINKSHEETS: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products is pleased to report that progress is being made towards the acquisition of new expanded lab facilities in preparation for a major pre-clinical trial utilizing its proprietary non-embryonic stem cell technology. The Company's efforts also continue to be focused on opportunities and collaborative efforts with the Economic Development Board of Singapore. These domestic and international efforts support the Company's pursuit of advanced scientific protocols in preparation for the first human clinical trials using the company's proprietary stem cell technology.
-- Healtheuniverse is completing formal due diligence towards the possible acquisition of additional lab facilities in the United States and is anticipating the disclosure of significant developments in the near- future.
-- The Company has completed formal due diligence with the Economic Development Board of Singapore and expects major pre-clinical research to begin soon. Further information will be provided to Healtheuniverse's shareholders as soon as possible.
-------------------- COMMUNICATION CAUSES LEARNING!!!!! Posts: 136 | From: Ahwahnee, Ca | Registered: Apr 2006
| IP: Logged |
Total current assets : 857,114 Total current liabilities : 189,194
Net income : -13,736 Ending retained earnings : 60,636
Common stock $.001 par value, 200,000,000 authorized, 55,220,000 shares issued and outstanding : 78,900 additional paid in capital : 75,100 Unrealized gain on trading securities : 460,220 Retained Earnings : 60,636
Owns Bollywood flix LLC, an online video and audio distribution company.
-------------------- COMMUNICATION CAUSES LEARNING!!!!! Posts: 136 | From: Ahwahnee, Ca | Registered: Apr 2006
| IP: Logged |
posted
I personally believe this company to be a sleeper. It is sitting at the bottom of its chart, and has not had much notice of any kind.
The company seems to have good potential to grow, but I think that it is in the very early stages at this point. I am not positive if there will be any major developments that will kick this stock into gear, but I am holding onto a small number of shares in hopes that the NON-EMBRYIONIC stem cells will have a much higher approval rating and will facilitate HLUN getting funding from the government.
The following is a kinda propaganda page put out April 11, 2006 after the announcement of the acquisition.
The bottom has been hit IMO, and the past couple of weeks have shown the support to be at .10 In the month of June, HLUN could have been flipped 4 times. Twice for .03/share gain and twice for .05/share gain.
-------------------- COMMUNICATION CAUSES LEARNING!!!!! Posts: 136 | From: Ahwahnee, Ca | Registered: Apr 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
